UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES AND EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): June 28, 2007
DYNAVAX TECHNOLOGIES
CORPORATION
(Exact name of registrant as specified in charter)
| |
|
|
|
|
Delaware
(State or other
jurisdiction of
incorporation)
|
|
000-50577
(Commission File Number)
|
|
33-0728374
(I.R.S. Employer
Identification No.) |
2929 Seventh Street, Suite 100
Berkeley, California 94710
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (510) 848-5100
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
1
Item 8.01. Other Events.
In a press release dated June 28, 2007, Dynavax Technologies Corporation (“Dynavax”) announced
that it has entered into a license agreement with Coley Pharmaceutical Group, Inc. (“Coley”)
relating to certain of Coley’s TLR Therapeutics™ patents. Under the terms of the agreement, Dynavax
receives a non-exclusive license under Coley’s immunostimulatory oligonucleotide patent estate for
the commercialization of HEPLISAV™, a hepatitis B prophylactic vaccine, currently in Phase 3
clinical trials. Dynavax will make a $5.0 million up-front payment to Coley. Coley is also eligible
to receive up to an additional $5.0 million upon regulatory approvals of HEPLISAV™, as well as
royalty payments for any future sales of HEPLISAV™.
The press release dated June 28, 2007, titled “Coley Pharmaceutical Group Grants Dynavax
License for Commercialization of HEPLISAV™” is attached hereto as Exhibit 99.1 and is herein
incorporated by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| |
|
|
| Exhibit No. |
|
Description |
99.1
|
|
Press release, dated June 28, 2007, entitled “Coley
Pharmaceutical Group Grants Dynavax License for
Commercialization of HEPLISAV™.” |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| |
|
|
|
|
| |
Dynavax Technologies Corporation
|
|
| Dated: July 2, 2007 |
By: |
/s/ Michael Ostrach
|
|
| |
|
Michael Ostrach, Vice President, Chief |
|
| |
|
Business Officer and General Counsel |
|
3